(kroe TAM i tonn)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Eurax: 10% (60 g)
Eurax: 10% (60 g, 454 g)
Brand Names: U.S.
- Scabicidal Agent
Crotamiton has scabicidal activity against Sarcoptes scabiei; mechanism of action unknown. Antipruritic effects mediated by inhibition of histamine, serotonin, and PAR-2 (Sekine 2012).
Amount of systemic absorption following topical use has not been determined
Use: Labeled Indications
Treatment of scabies (Sarcoptes scabiei) and symptomatic treatment of pruritus
Hypersensitivity to crotamiton or any component of the formulation; patients who manifest a primary irritation response to topical medications
Pruritus: Adults: Topical: Massage into affected areas until medication is completely absorbed; repeat as necessary
Scabicide: Adults: Topical: Apply a thin layer and massage drug onto skin of the entire body from the neck to the toes (with special attention to skin folds, creases, and interdigital spaces). Repeat application in 24 hours. May re-treat if new lesions appear or itching persists more than 2 to 4 weeks after initial treatment (CDC 2010).
Topical: For external use only; avoid eyes and mucous membranes. Shake lotion well before using. Take a bath or shower prior to application. Apply from neck down to toes. Trim fingernails and apply under nails (can use toothbrush, which should be disposed of after use). Take a cleansing bath 48 hours after the final application. Contaminated clothing and bed linens should be washed on hot cycle or dry-cleaned and all clothing and bedding should be changed the day after application.
Store at room temperature.
There are no known significant interactions.
Frequency not defined. Topical:
Dermatologic: Contact dermatitis, pruritus, rash
Local: Local irritation
Miscellaneous: Allergic sensitivity reactions, warm sensation
• Appropriate use: For external use only; avoid contact with face, eyes, mucous membranes, and urethral meatus. Do not apply to acutely inflamed, raw, or weeping skin. Discontinue use if severe irritation or sensitization occurs.
Pregnancy Risk Factor
Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber live mites or severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.